Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Nike assumed at Buy, 'near-term challenges well understood': 4 big analyst picks

Published 12/05/2023, 06:34 AM
© Reuters.

Investing.com — Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: Buy assumptions at Nike and Block, and upgrades at Crown Castle and Apellis Pharmaceuticals.

Unlock the potential of InvestingPro for up to 60% off this Cyber Monday Extended and never miss out on a market winner again.

Nike assumed with Buy at Goldman Sachs

Goldman Sachs assumed coverage on Nike (NYSE:NKE) with a Buy rating and a price target of $139.00 (from $136 prior), as reported in real-time on InvestingPro.

The analysts expect an upturn in Nike's earnings growth. This optimism stems from anticipated benefits from transitory cost recapture and improving inventory conditions in the market. The analysts also foresee a potential for higher revenue growth as Nike moves past difficult comparison periods and boosts its innovation and marketing engine in 2024.

Although the bank acknowledges near-term challenges, including increased competition, wholesale channel pressures, and diminishing impacts from specific growth factors (such as Jordan Brand, China market), it considers these to be already factored into Nike's attractive valuation.

The company is set to report its Q2/24 earnings on Dec 21.

cyber monday

Block assumed with Outperform rating

BMO Capital assumed coverage on Block (NYSE:SQ) with an Outperform rating and a price target of $84.00.

The analysts expect sustained gross profit growth in both the Cash App and Square Seller in the medium term. Additionally, the analysts predict a heightened focus on improving profit margins.

Despite acknowledging significant execution risk in achieving Block's targets for 2026, the analysts believe that the company has opportunities for immediate cost-saving measures that could positively influence market sentiment in the short term.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Two more upgrades

Wells Fargo upgraded Crown Castle International (NYSE:CCI) to Equal Weight from Underweight and raised its price target to $115.00 from $90.00.

BofA Securities upgraded Apellis Pharmaceuticals (NASDAQ:APLS) to Buy from Neutral and raised its price target to $85.00 from $52.00. As a result, shares gained more than 3% pre-market today.

Missed out on Black Friday? No problem, we've got you covered for Cyber Monday Extended at InvestingPro! There's still time to enjoy generous discounts. Elevate your market research with faster data, giving you the edge you need. Don't let this opportunity pass—act now and make your market insights even more powerful.

cyber monday

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.